Literature DB >> 9636861

Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children.

E H Choi1, H J Lee.   

Abstract

One hundred six cases of invasive pneumococcal infections diagnosed from 1985 to 1996 were analyzed retrospectively. The types of infection were bacteremia without focus (45%), meningitis (19%), peritonitis (17%), pneumonia (bacteremic) (16%), and others (3%). Penicillin-nonsusceptible Streptococcus pneumoniae was first detected in 1989, and its incidence increased rapidly thereafter, reaching 89% in 1995. Initial empirical regimens were of parenteral beta-lactam antimicrobials with or without an aminoglycoside, but these were modified subsequently. Among the 72 nonmeningeal infections analyzed, a favorable response at 72 hours and death were observed in 83% and 2.5%, respectively, of 40 penicillin-susceptible infections, as compared with 86% (P = 1.0) and 7.1% (P = .45) of 14 infections due to intermediate strains and 61% (P = .07) and 11% (P = .22) of 18 due to resistant strains. The favorable-response rate and mortality among 49 patients not in initially critical condition were 92% and zero, respectively, as compared with 52% (P = .00027) and 17% (P = .008) of 23 in critical condition. The data suggest that clinical outcome of penicillin-nonsusceptible pneumococcal infection outside the CNS may be more closely related to clinical condition at presentation than to the level of resistance of the causative strain when such infection is treated with parenteral beta-lactams.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9636861     DOI: 10.1086/516340

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  8 in total

1.  Impact of penicillin nonsusceptibility on clinical outcomes of patients with nonmeningeal Streptococcus pneumoniae bacteremia in the era of the 2008 clinical and laboratory standards institute penicillin breakpoints.

Authors:  Seong-Ho Choi; Jin-Won Chung; Heungsup Sung; Mi-Na Kim; Sung-Han Kim; Sang-Oh Lee; Yang Soo Kim; Jun Hee Woo; Sang-Ho Choi
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

Review 2.  Penicillin- and cephalosporin-resistant Streptococcus pneumoniae. Emerging treatment for an emerging problem.

Authors:  K P Klugman; C Feldman
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

3.  Invasive pneumococcal disease in Oxford, 1985-2001: a retrospective case series.

Authors:  C C Grant; A R Harnden; G Jewell; K Knox; T E Peto; D W Crook
Journal:  Arch Dis Child       Date:  2003-08       Impact factor: 3.791

4.  Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model.

Authors:  Holly L Hoffman; Michael E Klepser; Erika J Ernst; C Rosemarie Petzold; Loai Mohammed Sa'adah; Gary V Doern
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

5.  Treatment of community-acquired pneumonia, with special emphasis on gemifloxacin.

Authors:  Serkan Oncü
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

Review 6.  The changing epidemiology of childhood pneumococcal disease in Korea.

Authors:  Young June Choe; Eun Hwa Choi; Hoan Jong Lee
Journal:  Infect Chemother       Date:  2013-06-26

7.  Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults.

Authors:  Lionel A Mandell; John G Bartlett; Scott F Dowell; Thomas M File; Daniel M Musher; Cynthia Whitney
Journal:  Clin Infect Dis       Date:  2003-11-03       Impact factor: 9.079

8.  Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea.

Authors:  Hye-Young Kim; Seong-Beom Park; Eun-Sil Kang; Sang-Min Lee; Hyun-Jin Kim; Matt Wasserman
Journal:  Hum Vaccin Immunother       Date:  2020-08-12       Impact factor: 3.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.